Delivery strategies to enhance mucosal vaccination

Expert Opinion on Biological Therapy

Volumn 9, Issue 4, 2009, Pages 427-440

  Chadwick, Sandra ^a   Kriegel, Christina ^a   Amiji, Mansoor ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Delivery vehicles; Immuno adjuvants; Mucosal immune system; Vaccination strategies

Indexed keywords

ALUMINUM HYDROXIDE; ANTISENSE OLIGONUCLEOTIDE; BCG VACCINE; CHITOSAN; CHOLERA TOXIN; COLLAGEN; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; GELATIN; GOLD; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMIQUIMOD; LIPOPOLYSACCHARIDE; LIPOSOME; MACROGOL; MURAMYL DIPEPTIDE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NAKED DNA; OVALBUMIN; PHOSPHORYL LIPID A; POLOXAMER; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIDE; POLYLYSINE; POLYRIBONUCLEOTIDE; PRASTERONE; SUBUNIT VACCINE; UNINDEXED DRUG; WART VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT THERAPY; CELLULAR IMMUNITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG STORAGE; DRUG TARGETING; EMULSION; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; INFECTION PREVENTION; JET INJECTOR; MUCOSAL IMMUNITY; REVIEW; TUBERCULOSIS; VACCINATION; VACCINE PRODUCTION;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION SCHEDULE; VACCINATION; VACCINES;

EID: 67649298021     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590902849224     Document Type: Review

References (103)

1. Heystek HC, Moulon C, Woltman AM, et al. Human immature dendritic cells efficiently bind and take up Secretory IgA without the induction of maturation. J Immunol 2002;168:102-107 (Pubitemid 34014108)
2. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 2001;14:430-445 • This paper reviews parallel material concerning the mucosal immune system, types of vaccines and strategies to enhance mucosal immune responses both generally and in relation to specific challenges. (Pubitemid 32294678)
3. Clark MA, Jepson MA, Hirst BH. Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev 2001;50:81-106 • This paper covers the structure and function of M-cells and their importance in vaccine delivery as well as M-cell targeting strategies. (Pubitemid 32727278)
4. Brandtzaeg P, Kiyono H, Pabst R, Russell MW. Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol 2008;1:31-37 • This paper systematically describes the components of the mucosal immune system and their purpose both individually and as related to the immune system as a whole.
5. Neutra MR. Interactions of viruses and microparticles with apical plasma membranes of M cells: implications for human immunodeficiency virus transmission. J Infectious Dis 1999;179:S441-3 (Pubitemid 29198394)
6. Neutra MR. Current concepts in mucosal immunity V. Role of M cells in transepithelial transport of antigens and pathogens to the mucosal immune system. Am J Gastrointest Liver Physiol 1998;274:785-791 (Pubitemid 28289505)
7. Jang MH, Kweon MN, Iwatani K, et al. Intestinal villous M cells: an antigen entry site in the mucosal epithelium. PNAS 2004;101:6110-6115 (Pubitemid 38520536)
8. Gebert A, Steinmetz I, Fassbender S, Wendlandt KH. Antigen transport into Peyer's patches: increased uptake by constant numbers of M cells. Am J Pathol 2004;164:65-72 (Pubitemid 38364591)
9. Van Der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan for mucosal vaccination. Adv Drug Deliv Rev 2001;52:139-144 (Pubitemid 33079169)
10. Fujihashi K, Dohi T, Rennert PD, et al. Peyer's patches are requried for oral tolerance to proteins. PNAS 2001;98:3310-3315 (Pubitemid 32220842)
11. Van Ginkel FW, Nguyen HH, McGhee JR. Vaccines for mucosal immunity to combat emerging infectious diseases. Emerg Infectious Dis 2000;6:123-132 • This paper describes the activation of various pathways in the mucosal immune system and how each will result in different overall immune responses. (Pubitemid 30226889)
12. Goodsell A, Zhou F, Gupta S, et al. β7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery. Immunology 2007;123:378-389
13. Kieny MP, Excler JL, Girard M. Research and development of new vaccines against infectious diseases. Am J Public Health 2004;94:1931-1935 (Pubitemid 39434823)
14. Webster D, Gahan ME, Strugnell RA, Wesselingh SL. Advances in oral vaccine delivery options: What is on the horizon? Am J Drug Deliv 2003;1:227-240 • This paper reviews various methods of vaccine delivery specifically related to the oral administration route and how the mucosal immune system is inherently involved in this process.
15. Burgdorf S, Kautz A, Bohnert V, et al. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 2007;316:612-616 (Pubitemid 46683149)
16. Malyguine A, Strobl SL, Shafer-Weaver KA, et al. A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. J Transl Med 2004;2(1):9 Published online 29 March 2004, doi:10.1186/1479-5876-2-9 (Pubitemid 39130362)
17. Rosemberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-384 • This paper discusses the use of immunotherapy against cancerous tissue and how the immune system can be activated and directed against tumor antigens.
18. Bermúdez-Humarán LG, Cortes-Perez NG, Lefèvre F, et al. A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005;175:7297-7302 (Pubitemid 41713425)
19. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006;116:1167-1173 • This paper exemplifies the successful development and use of a prophylactic vaccine against human papillomavirus.
20. Ahuja SS, Estrada CA, Lindsey ML. Crosstalk between cytotoxic T-lymphocyte associated antigen-4 and interleukin-12 in cytotoxic T-lymphocyte mediated myocarditis: adding another link to the chain. Circ Res 2007;101:218-220 (Pubitemid 47344067)
21. Brandtzaeg P. Nature and function of gastrointestinal antigen-presenting cells. Allergy 2001;56:16-20 (Pubitemid 32545228)
22. Srivastava IK, Singh M. DNA vaccines: focus on increasing potency and efficacy. Int J Pharm Med 2005;19:15-28 • This paper reviews the challenges of DNA vaccines as related to induction of both cytotoxic T-cell responses and humoral responses as well as DNA vaccine delivery. (Pubitemid 43305328)
23. Cossart P, Sansonetti PJ. Bacterial invasion: the paradigms of enteroinvasive pathogens. Science 2004;304:242-248 (Pubitemid 38452169)
24. Roche S, Rey FA, Gaudin Y, Bressanelli S. Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G. Science 2007;315:843-848 (Pubitemid 46255836)
25. Sansonetti PJ, Di Santo JP. Debugging how bacteria manipulate the immune response. Immunity 2007;26:149-161 (Pubitemid 46329442)
26. Horwitz MA, Harth G, Dillon, BJ, Masleša-Galic S. Recombinant bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000; 97(25):13853-13858
27. Khader SA, Bell GK, Pearl JE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007;8:369-377 (Pubitemid 46745412)
28. Bhavsar MD, Amiji MM. Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. AAPS PharmSciTech 2008;9:288-294
29. Azad N, Rojanasakul Y. Nanobiotechnology in drug delivery. Am J Drug Deliv 2006;4:79-88 • This paper reviews various nanodelivery systems for use in pharmaceuical applications including the delivery of proteins, genetic material and vaccines. (Pubitemid 44049542)
30. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 2008;6:349-362 (Pubitemid 351552656)
31. Donnelly JJ, Wahren B, Liu MA, et al. DNA vacines: progress and challenges. J Immunol 2005;175:633-639 • This paper reviews the mechanism of DNA vaccines and both existing challenges and recent improvements in their successful application.
32. Kahatri K, Goyal AK, Gupta PN, et al. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. Int J Pharm 2008;354:235-241
33. Bhavsar MD, Amiji MM. Polymeric nano- and microparticle technologies for oral gene delivery. Expert Opin Drug Deliv 2007;4:197-213 • This review discusses polymeric delivery systems for the delivery of genetic material by oral administration. (Pubitemid 46767624)
34. Wang J, Thorson L, Stokes RW, et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004;173:6357-6365 • This paper describes the use of recombinant Adenovirus-based vaccines for the induction of protection against mucosal-transmitted disease. (Pubitemid 39487795)
35. Lin SW, Hensley SE, Tatsis N, et al. Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J Clin Invest 2007;117:3958-3970 (Pubitemid 350224105)
36. Boyer JD, Cohen AD, Vogt S, et al. Vaccination of seronegative volunteers with a human immunodeficiency virus Type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of β-chemokines. J Infect Dis 2000;181:476-483 (Pubitemid 30131813)
37. Maecker HT, Hansen G, Walter DM, et al. Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model. J Immunol 2001;166:959-965 (Pubitemid 32060251)
38. Maecker H, Umetsu DT, DeKruyff RH, Levy S. DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin. Vaccine 1997;15:1687-1696 (Pubitemid 27445749)
39. Belyakov IM, Isakov D, Zhu Q, et al. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/ human immunodeficiency viral depletion of mucosal CD4+ T cells. J Immunol 2007;178:7211-7221 (Pubitemid 46847447)
40. Badovinac VP, Messingham KA, Jabbari A, et al. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med 2005;11:748-756 (Pubitemid 41021207)
41. Yanagita M, Hiroi T, Kitagaki N, et al. Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production. J Immunol 1999;162:3559-3565 (Pubitemid 29313609)
42. Gallichan WS, Rosenthal KL. Long-lived cytotoxic T lymphocyte memory in mucosal tissue after mucosal but not systemic immunization. J Exp Med 1996;184:1879-1890 • This paper discusses the importance of the route of immunization in the activation of immunological memory. (Pubitemid 26404478)
43. Tanghe A, D'Souza S, Rosseels V. Improved immunogenicty and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun 2001;69:3041-3047 • This paper evaluates the different immune responses that can be elicited by different types of vaccines and how they can be used synergistically. (Pubitemid 32332198)
44. Horner AA, Datta SK, Takabayashi K, et al. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J Immunol 2001;167:1584-1591 (Pubitemid 32703159)
45. Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 2005;172:1487-1490 (Pubitemid 43076534)
46. Ishii T, Okahata Y, Sato T. Mechanism of cell transfection with plasmid/chitosan complexes. Biochemica et Biophysica Acta 2001;1514:51-64 (Pubitemid 32769928)
47. Bhavsar MD, Amiji MM. Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J Control Release 2007;119:339-348 (Pubitemid 46770879)
48. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. PNAS 2006;103:4930-4934
49. Borchard G. Chitosans for gene delivery. Adv Drug Deliv Rev 2001;52:145-150 (Pubitemid 33079170)
50. Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release 2008;126:187-204
51. Devalapally H, Duan Z, Seiden MV, Amiji MM. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin Cancer 2008;14:3193-3203
52. van Vlerken LE, Duan Z, Little SR, et al. Biodistribution and pharmacokinetic analysis of paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model. Mol Pharm 2008;5:516-526
53. Bhavsar MD, Tiwari SB, Amiji MM. Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J Control Release 2006;110:422-430 (Pubitemid 41827496)
54. Talsma SS, Babensee JE, Murthy N, Williams IR. Development and in vitro validation of a targeted delivery vehicle for DNA vaccines. J Control Release 2006;112:271-279
55. Diebold SS, Cotten M, Koch N, Zenke M. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther 2001;8:487-493 (Pubitemid 32266404)
56. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000;21:2475-2490 (Pubitemid 30700470)
57. Lamprecht A, Ubrich N, Yamamoto H, et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2001;299:775-781 (Pubitemid 32979694)
58. Fremont DH, Stura EA, Matsumura M, et al. Crystal structure of an H-2Kb-ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in the major histocompatibility complex binding groove. Immunology 1995;92:2479-2483
59. Kim TS, DeKruyff RH, Rupper R. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J Immunol 1997;158:4137-4144 (Pubitemid 127483912)
60. Kaul G, Amiji M. Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: in vitro and in vivo studies. Pharm Res 2005;22:951-961 (Pubitemid 40898105)
61. Zwiorek K, Kloeckner J, Wagner E, Coester C. Gelatin nanoparticles as a new and simple gene delivery system. J Pharm Pharm Sci 2004;7:22-28 (Pubitemid 41522055)
62. Baca-Estrada ME, Foldvari M, Babuik SL, Babuik LA. Vaccine delivery: lipid-based delivery systems. J Biotechnol 2000;83:91-104 (Pubitemid 30734752)
63. Filipovi -Gr i J, Škalko-Basnet N, JalŠienjak I. Mucoadhesive chitosan-coated liposomes: characteristics and stability. J Microencapsul 2001;18:3-12 • This paper describes the use of targeting components incorporated into carrier systems to improve delivery in vivo
64. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. PNAS 2001;98:8786-8791 (Pubitemid 32678105)
65. Sakaue G, Hiroi T, Nakagawa Y, et al. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J Immunol 2003;170:495-502 (Pubitemid 36026176)
66. Kwak LW, Pennington R, Boni L, et al. Cutting edge: Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. J Immunol 1998;160:3637-3641 • This paper describes methods for producing emulsion carrier systems incorporating adjuvant components and the resulting immune responses induced. (Pubitemid 28176062)
67. Allison AC. Squalene and squalane emulsions as adjuvants. Methods 1999;19:87-93 (Pubitemid 29497757)
68. Bozkir A, Hayta G. Preparation and evaluation of multiple emulsions water-in-oil-in-water (w/o/w) as delivery system for influenza virus antigens. J Drug Target 2004;12:157-164 (Pubitemid 38868163)
69. Hanson JA, Chang CB, Graves SM, et al. Nanoscale double emulsions stabilized by single-component block copolypeptides. Nature 2008;455:85-88 • This paper discusses methods for the production of emulsions that can be used as carrier systems.
70. Shahiwala A, Amiji MM. Enhanced mucosal and systemic immune response with sqalane oil-containing multiple emulsions upon intranasal and oral administration in mice. J Drug Target 2008;16:302-310 • This paper compares the immune response induced after intranasal or oral administration of vaccines in adjuvant-containing emulsion systems. (Pubitemid 351622360)
71. Yih TC, Al-Fandi M. Engineered nanoparticles as precise drug delivery systems. J Cell Biochem 2006;97:1184-1190
72. Bhattacharya R, Mukherjee P. Biological properties of "naked" metal nanoparticles. Adv Drug Deliv Rev 2008;60:1289-1306 • This paper describes the use of metal nanoparticles as immunological adjuvants and drug carrier systems.
73. Mukherjee P, Bhattacharya R, Bone N, et al. Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. J Nanobiotechnol 2007;5:4. Published online 8 May 2007doi:10.1186/1477-3155-5-14 (Pubitemid 46851043)
74. Greenberg RS, Maxwell LG, Zahurak M, Yaster M. Preanesthetic medication of children with midazolam using the biojector jet injector. Anesthesiology 1995;83:264-269
75. Harrison RA, Bianco AE. DNA immunization with Onchocerca volvulus genes, Ov-tmy-1 and OvB20: serological and parasitological outcomes following intramuscular or GeneGun delivery in a mouse model of Onchocerciasis. Parasite Immunol 2000;22:249-257
76. Robinson HL, Montefiori DC, Johnson RP, et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant poxvirus booster immunizations. Nat Med 1999;5:526-534 (Pubitemid 29220211)
77. Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 1997;158:2278-2284 (Pubitemid 127470012)
78. Wang R, Epstein J, Baraceros FM, et al. Induction of CD4+ T cell-dependent CD8+ type 1 responses in humans by a malaria DNA vaccine. PNAS 2001;98:10817-10822 (Pubitemid 32878703)
79. Marshall L, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18:3964-3973
80. Rogers WO, Baird JK, Kumar A, et al. Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in Rhesus Macaques. Infect Immun 2001;69:5565-5572 (Pubitemid 32786492)
81. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292:69-74 (Pubitemid 32289126)
82. Higgins LM, Lambkin I, Donnelly G, et al. In vivo phage display to identify M cell-targeting ligands. Pharm Res 2004;21:695-705
83. Orme I. Tuberculosis vaccines: current progress. Drugs 2005;65:2437-2444 (Pubitemid 41697313)
84. Lelouard H, Reggio H, Roy C, et al. Glycocalyx on rabbit intestinal M cells displays carbohydrate epitopes from Muc2. Infect Immun 2001;69:1061-1071 (Pubitemid 32109574)
85. Sansonetti P. Host-pathogen interactions: the seduction of molecular cross talk. Gut 2002;50(Suppl 3):iii2-8 (Pubitemid 34407449)
86. Nochi T, Yuki Y, Matsumura A, et al. A novel M cell - specific carbohydrate targeted mucosal vaccine effectively induces antigen-specific immune responses. J Exp Med 2007;204:2789-2796 (Pubitemid 350179549)
87. Issa MM, Köping-Höggård M, Tømmeraas K, et al. Targeted gene delivery with trisaccharide-substituted chitosan oligomers in vitro and after lung administration in vivo. J Control Release 2006;115:103-112 (Pubitemid 44415074)
88. Bacon A, Makin J, Sizer PJ, et al. Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun 2000;68:5764-5770 • This paper evaluates the use of different mucosa-targeting components for improving the immune response to mucosal vaccines. (Pubitemid 30739363)
89. Gullberg E, Keita AV, Salim SY, et al. Identification of cell adhesion molecules in the human follicle-associated epithelium that improve nanoparticle uptake into the Peyer's patches. J Pharmacol Exp Ther 2006;319:632-639 (Pubitemid 44776366)
90. Wu Y, Wang X, Csencsits KL. M cell-targeted DNA vaccination. PNAS 2001;98:9318-9323 (Pubitemid 32743914)
91. Cox E, Verdonck F, Vanrompay D, Goddeeris B. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet Res 2006;37:511-539 • This paper reviews a range of mucosal adjuvants and how they impact the strength and focus of the immune response. (Pubitemid 43725034)
92. Horwitz MA, Harth G, Dillon BJ, MasleŠa-Gali S. Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein. Infect Immun 2005;73:4676-4683 (Pubitemid 41105623)
93. Kaminski RW, Turbyfill KR, Oaks EV. Mucosal adjuvant properties of the Shigella invasin complex. Infect Immun 2006;74:2856-2866 (Pubitemid 43672996)
94. Akhiani AA, Stensson A, Schön K, Lycke N. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization. J Immunol 2006;63:97-105
95. Johnson AG. Molecular adjuvants and immunomodulators: New approaches to immunization. Clin Microbiol Rev 1994;7:277-289 (Pubitemid 24216121)
96. Alignani D, Maletto B, Liscovsky M, et al. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice. J Leukoc Biol 2005;77:898-905 (Pubitemid 40770841)
97. Giri PK, Khuller GK. Is intranasal vaccination a feasible solution for tuberculosis? Expert Rev Vaccines 2008;7:1341-1356
98. Selinsky C, Luke C, Wlock M, et al. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum Vaccines 2005;1:16-23
99. Little SF, Ivins BE, Webster WM, et al. Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine. Vaccine 2007;25:2771-2777 (Pubitemid 46412577)
100. Sun RWY, Chen R, Chung NPY, et al. Silver nanoparticles fabricated in Hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells. Chem Commun (Camb) 2005;28(40):5059-5061 (Pubitemid 41566432)
101. Elechiguerra JL, Burt JL, Morones JR, et al. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnol 2005;3:6. Published online 29 June 2005 doi:10.1186/1477-3155-3-6 (Pubitemid 41460801)
102. Maecker HT, Umetsu DT, DeKruyff RH, Levy S. DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin. Vaccine 1997;15:1687-1696 (Pubitemid 27445749)
103. Rich RR, Fleischer TA, Shearer WT, Kotzin BL, Schroeder HW Jr, editors, Clin Immunol London: Mosby, 2001